EUnetHTA Magazine – Winter 2021 – now available
We are please to finally publish another issue of the EUnetHTA Magazine, a collection of articles submitted by members and stakeholders that deal with HTA in Europe, EUnetHTA tasks and output, and, of course, COVID-19 and the network's reprioritization this
EUnetHTA – Open Letter of Comment
This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within European HTA, and that of scientific journals. Please access the letter here: EUnetHTA - Open Letter of
PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.
This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen
Patient group input requested for a new Joint Assessment on a medicinal product for cerebral adrenoleukodystrophy (CALD).
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We
PTRCR15 – remdesivir for the treatment of COVID-19. First update, December 2020.
In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This is the first update on the pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. Following the original Rapid Collaborative
Patient group input requested for a new Joint Assessment on a medicinal product for acute myeloid leukaemia (AML).
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We
PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing
OTCA26 Obesity Surgery Project – Project Plan now available
EUnetHTA is pleased to announce the project description and planning for 26th Other Technologies Collaborative Assessment "Surgical procedures for treatment of obesity" is now available for access. The relevance of the topic lies in evidence suggesting that bariatric surgery decreases the
Final Week – EUnetHTA Open Call for Early Dialogue Requests
The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open